BioCentury
ARTICLE | Clinical News

Vertex, Alios discontinue one NS5B nuc, report data for another

September 26, 2012 1:00 AM UTC

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and partner Alios BioPharma Inc. (South San Francisco, Calif.) discontinued development of ALS-2158 after a Phase I HCV trial of the nucleotide HCV NS5B polymerase inhibitor showed "insufficient antiviral activity to warrant proceeding with further clinical development." Vertex declined to provide details regarding the discontinuation. ...